Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice

Many studies have suggested that the renin-angiotensin system plays an important role in the development of pressure overload-induced cardiac hypertrophy. Moreover, it has been reported that pressure overload-induced cardiac hypertrophy is completely prevented by ACE inhibitors in vivo and that the...

Full description

Saved in:
Bibliographic Details
Published inCirculation (New York, N.Y.) Vol. 97; no. 19; pp. 1952 - 1959
Main Authors HARADA, K, KOMURO, I, YAZAKI, Y, SHIOJIMA, I, HAYASHI, D, KUDOH, S, MIZUNO, T, KIJIMA, K, MATSUBARA, H, SUGAYA, T, MURAKAMI, K
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 19.05.1998
American Heart Association, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Many studies have suggested that the renin-angiotensin system plays an important role in the development of pressure overload-induced cardiac hypertrophy. Moreover, it has been reported that pressure overload-induced cardiac hypertrophy is completely prevented by ACE inhibitors in vivo and that the stored angiotensin II (Ang II) is released from cardiac myocytes in response to mechanical stretch and induces cardiomyocyte hypertrophy through the Ang II type 1 receptor (AT1) in vitro. These results suggest that the AT1-mediated signaling is critical for the development of mechanical stress-induced cardiac hypertrophy. To determine whether AT1-mediated signaling is indispensable for the development of pressure overload-induced cardiac hypertrophy, pressure overload was produced by constricting the abdominal aorta of AT1A knockout (KO) mice. Quantitative reverse transcriptase-polymerase chain reaction revealed that the cardiac AT1 (probably AT1B) mRNA levels in AT1A KO mice were <10% of those of wild-type (WT) mice and were not affected by pressure overload. Chronic treatment with subpressor doses of Ang II increased left ventricular mass in WT mice but not in KO mice. Pressure overload, however, fully induced cardiac hypertrophy in KO as well as WT mice. There were no significant differences between WT and KO mice in expression levels of fetal-type cardiac genes, in the left ventricular wall thickness and systolic function as revealed by the transthoracic echocardiogram, or in the histological changes such as myocyte hypertrophy and fibrosis. AT1-mediated Ang II signaling is not essential for the development of pressure overload-induced cardiac hypertrophy.
AbstractList Many studies have suggested that the renin-angiotensin system plays an important role in the development of pressure overload-induced cardiac hypertrophy. Moreover, it has been reported that pressure overload-induced cardiac hypertrophy is completely prevented by ACE inhibitors in vivo and that the stored angiotensin II (Ang II) is released from cardiac myocytes in response to mechanical stretch and induces cardiomyocyte hypertrophy through the Ang II type 1 receptor (AT1) in vitro. These results suggest that the AT1-mediated signaling is critical for the development of mechanical stress-induced cardiac hypertrophy. To determine whether AT1-mediated signaling is indispensable for the development of pressure overload-induced cardiac hypertrophy, pressure overload was produced by constricting the abdominal aorta of AT1A knockout (KO) mice. Quantitative reverse transcriptase-polymerase chain reaction revealed that the cardiac AT1 (probably AT1B) mRNA levels in AT1A KO mice were <10% of those of wild-type (WT) mice and were not affected by pressure overload. Chronic treatment with subpressor doses of Ang II increased left ventricular mass in WT mice but not in KO mice. Pressure overload, however, fully induced cardiac hypertrophy in KO as well as WT mice. There were no significant differences between WT and KO mice in expression levels of fetal-type cardiac genes, in the left ventricular wall thickness and systolic function as revealed by the transthoracic echocardiogram, or in the histological changes such as myocyte hypertrophy and fibrosis. AT1-mediated Ang II signaling is not essential for the development of pressure overload-induced cardiac hypertrophy.
BACKGROUND: Many studies have suggested that the renin-angiotensin system plays an important role in the development of pressure overload-induced cardiac hypertrophy. Moreover, it has been reported that pressure overload-induced cardiac hypertrophy is completely prevented by ACE inhibitors in vivo and that the stored angiotensin II (Ang II) is released from cardiac myocytes in response to mechanical stretch and induces cardiomyocyte hypertrophy through the Ang II type 1 receptor (AT1) in vitro. These results suggest that the AT1-mediated signaling is critical for the development of mechanical stress-induced cardiac hypertrophy. METHODS AND RESULTS: To determine whether AT1-mediated signaling is indispensable for the development of pressure overload-induced cardiac hypertrophy, pressure overload was produced by constricting the abdominal aorta of AT1A knockout (KO) mice. Quantitative reverse transcriptase-polymerase chain reaction revealed that the cardiac AT1 (probably AT1B) mRNA levels in AT1A KO mice were 10% of those of wild-type (WT) mice and were not affected by pressure overload. Chronic treatment with subpressor doses of Ang II increased left ventricular mass in WT mice but not in KO mice. Pressure overload, however, fully induced cardiac hypertrophy in KO as well as WT mice. There were no significant differences between WT and KO mice in expression levels of fetal-type cardiac genes, in the left ventricular wall thickness and systolic function as revealed by the transthoracic echocardiogram, or in the histological changes such as myocyte hypertrophy and fibrosis. CONCLUSIONS: AT1-mediated Ang II signaling is not essential for the development of pressure overload-induced cardiac hypertrophy.
BACKGROUNDMany studies have suggested that the renin-angiotensin system plays an important role in the development of pressure overload-induced cardiac hypertrophy. Moreover, it has been reported that pressure overload-induced cardiac hypertrophy is completely prevented by ACE inhibitors in vivo and that the stored angiotensin II (Ang II) is released from cardiac myocytes in response to mechanical stretch and induces cardiomyocyte hypertrophy through the Ang II type 1 receptor (AT1) in vitro. These results suggest that the AT1-mediated signaling is critical for the development of mechanical stress-induced cardiac hypertrophy.METHODS AND RESULTSTo determine whether AT1-mediated signaling is indispensable for the development of pressure overload-induced cardiac hypertrophy, pressure overload was produced by constricting the abdominal aorta of AT1A knockout (KO) mice. Quantitative reverse transcriptase-polymerase chain reaction revealed that the cardiac AT1 (probably AT1B) mRNA levels in AT1A KO mice were <10% of those of wild-type (WT) mice and were not affected by pressure overload. Chronic treatment with subpressor doses of Ang II increased left ventricular mass in WT mice but not in KO mice. Pressure overload, however, fully induced cardiac hypertrophy in KO as well as WT mice. There were no significant differences between WT and KO mice in expression levels of fetal-type cardiac genes, in the left ventricular wall thickness and systolic function as revealed by the transthoracic echocardiogram, or in the histological changes such as myocyte hypertrophy and fibrosis.CONCLUSIONSAT1-mediated Ang II signaling is not essential for the development of pressure overload-induced cardiac hypertrophy.
Background —Many studies have suggested that the renin-angiotensin system plays an important role in the development of pressure overload–induced cardiac hypertrophy. Moreover, it has been reported that pressure overload–induced cardiac hypertrophy is completely prevented by ACE inhibitors in vivo and that the stored angiotensin II (Ang II) is released from cardiac myocytes in response to mechanical stretch and induces cardiomyocyte hypertrophy through the Ang II type 1 receptor (AT 1 ) in vitro. These results suggest that the AT 1 -mediated signaling is critical for the development of mechanical stress–induced cardiac hypertrophy. Methods and Results —To determine whether AT 1 -mediated signaling is indispensable for the development of pressure overload–induced cardiac hypertrophy, pressure overload was produced by constricting the abdominal aorta of AT 1A knockout (KO) mice. Quantitative reverse transcriptase–polymerase chain reaction revealed that the cardiac AT 1 (probably AT 1B ) mRNA levels in AT 1A KO mice were <10% of those of wild-type (WT) mice and were not affected by pressure overload. Chronic treatment with subpressor doses of Ang II increased left ventricular mass in WT mice but not in KO mice. Pressure overload, however, fully induced cardiac hypertrophy in KO as well as WT mice. There were no significant differences between WT and KO mice in expression levels of fetal-type cardiac genes, in the left ventricular wall thickness and systolic function as revealed by the transthoracic echocardiogram, or in the histological changes such as myocyte hypertrophy and fibrosis. Conclusions —AT 1 -mediated Ang II signaling is not essential for the development of pressure overload–induced cardiac hypertrophy.
Author HARADA, K
KOMURO, I
MATSUBARA, H
SUGAYA, T
KUDOH, S
KIJIMA, K
YAZAKI, Y
HAYASHI, D
SHIOJIMA, I
MIZUNO, T
MURAKAMI, K
Author_xml – sequence: 1
  givenname: K
  surname: HARADA
  fullname: HARADA, K
  organization: Department of Medicine III, University of Tokyo School of Medicine, Japan
– sequence: 2
  givenname: I
  surname: KOMURO
  fullname: KOMURO, I
  organization: Department of Medicine III, University of Tokyo School of Medicine, Japan
– sequence: 3
  givenname: Y
  surname: YAZAKI
  fullname: YAZAKI, Y
  organization: Department of Medicine III, University of Tokyo School of Medicine, Japan
– sequence: 4
  givenname: I
  surname: SHIOJIMA
  fullname: SHIOJIMA, I
  organization: Department of Medicine III, University of Tokyo School of Medicine, Japan
– sequence: 5
  givenname: D
  surname: HAYASHI
  fullname: HAYASHI, D
  organization: Department of Medicine III, University of Tokyo School of Medicine, Japan
– sequence: 6
  givenname: S
  surname: KUDOH
  fullname: KUDOH, S
  organization: Department of Medicine III, University of Tokyo School of Medicine, Japan
– sequence: 7
  givenname: T
  surname: MIZUNO
  fullname: MIZUNO, T
  organization: Department of Medicine III, University of Tokyo School of Medicine, Japan
– sequence: 8
  givenname: K
  surname: KIJIMA
  fullname: KIJIMA, K
  organization: Second Department of Internal Medicine, Kansai Medical University, Osaka, Japan
– sequence: 9
  givenname: H
  surname: MATSUBARA
  fullname: MATSUBARA, H
  organization: Second Department of Internal Medicine, Kansai Medical University, Osaka, Japan
– sequence: 10
  givenname: T
  surname: SUGAYA
  fullname: SUGAYA, T
  organization: Lead Generation Research Laboratories, Tanabe Seiyaku Co, Ltd, Osaka, Japan
– sequence: 11
  givenname: K
  surname: MURAKAMI
  fullname: MURAKAMI, K
  organization: Institute of Applied Biochemistry, University of Tsukuba, Ibaraki, Japan
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2242332$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/9609089$$D View this record in MEDLINE/PubMed
BookMark eNpdkEFr3DAQhUVJSTdJf0APBVFKb95qJMuSjmFp0oVAS2mvEdrxuHHilVzJLuy_r5csORQGZob3zWN4F-wspkiMvQOxBmjgs4A19nntzBrcUlq-YivQsq5qrdwZWwkhXGWUlG_YRSmPy9ooo8_ZuWuEE9at2P33TKXMmXj6S3lIoeV9bGekwjHktg_IHw4j5Smn8eGwaDzE332aKJZl3m75tKgcrnkmpHFKmT_FhE9pnvi-R7pir7swFHp76pfs182Xn5uv1d232-3m-q5CrWGq0FkgQt0qY83OkHT1zjYSILhOtsFIwNoaa1swDUqyWqPZhc4E6rBuENQl-_TsO-b0Z6Yy-X1fkIYhREpz8cY5UStpF_DDf-BjmnNcfvMSpAEjxRGCZwhzKiVT58fc70M-eBD-GLwX4DfbH94ZD84fg19u3p-M592e2peLU9KL_vGkh4Jh6HKI2JcXTMpaKiXVP2xejYg
CODEN CIRCAZ
CitedBy_id crossref_primary_10_1084_jem_20002036
crossref_primary_10_1093_cvr_cvac171
crossref_primary_10_1254_jjp_80_333
crossref_primary_10_1074_jbc_273_37_24037
crossref_primary_10_1111_jcmm_14308
crossref_primary_10_1152_ajpheart_2000_279_3_H976
crossref_primary_10_1016_j_ejps_2012_04_018
crossref_primary_10_1006_bbrc_2000_2561
crossref_primary_10_1016_S0165_6147_00_01679_5
crossref_primary_10_1016_S1357_2725_02_00344_8
crossref_primary_10_1093_emboj_cdg637
crossref_primary_10_1016_j_jacc_2003_07_021
crossref_primary_10_1038_nm805
crossref_primary_10_1073_pnas_97_2_931
crossref_primary_10_1254_jphs_FP0050160
crossref_primary_10_1161_HYPERTENSIONAHA_120_16915
crossref_primary_10_1152_ajpheart_2000_279_4_H1698
crossref_primary_10_1016_S0002_9149_99_00258_1
crossref_primary_10_1016_j_bbrc_2004_07_119
crossref_primary_10_1097_01_hjh_0000203843_41937_2a
crossref_primary_10_1016_j_jacc_2003_07_037
crossref_primary_10_1152_ajpheart_00361_2006
crossref_primary_10_1093_ndt_gfy006
crossref_primary_10_1016_j_pharmthera_2018_02_010
crossref_primary_10_1007_s10554_005_9052_9
crossref_primary_10_1097_FJC_0000000000001258
crossref_primary_10_1016_j_yjmcc_2006_05_006
crossref_primary_10_1097_FJC_0000000000000165
crossref_primary_10_1080_08037050152112087
crossref_primary_10_1155_2019_8768164
crossref_primary_10_1038_hr_2009_61
crossref_primary_10_1161_HYPERTENSIONAHA_113_02219
crossref_primary_10_1016_j_tibs_2004_09_002
crossref_primary_10_3390_cells9051092
crossref_primary_10_1042_CS20110176
crossref_primary_10_1139_y01_031
crossref_primary_10_1016_S0959_437X_99_80040_9
crossref_primary_10_1016_j_bbrc_2006_08_106
crossref_primary_10_1172_JCI10037
crossref_primary_10_1016_S0735_1097_00_01064_0
crossref_primary_10_1134_S1990747807010023
crossref_primary_10_1016_j_hfc_2005_03_006
crossref_primary_10_1006_jmcc_2002_2095
crossref_primary_10_1152_ajpheart_1999_277_1_H380
crossref_primary_10_1073_pnas_0811022106
crossref_primary_10_1007_BF01745045
crossref_primary_10_1016_j_mce_2014_10_003
crossref_primary_10_1097_FJC_0b013e31827a0278
crossref_primary_10_1253_circj_CJ_14_0470
crossref_primary_10_1097_00005344_200204000_00016
crossref_primary_10_1097_HJH_0b013e328338bb37
crossref_primary_10_1016_j_mce_2008_06_006
crossref_primary_10_1074_jbc_M100814200
crossref_primary_10_1074_jbc_M106132200
crossref_primary_10_1097_00004872_200204000_00035
crossref_primary_10_1089_ten_tea_2009_0434
crossref_primary_10_1371_journal_pone_0106354
crossref_primary_10_1016_S0033_0620_99_70019_8
crossref_primary_10_1097_CCM_0000000000000226
crossref_primary_10_1097_00005344_200312001_00014
crossref_primary_10_1038_hr_2011_217
crossref_primary_10_1152_physrev_00038_2017
crossref_primary_10_1007_s11906_000_0081_4
crossref_primary_10_1038_ki_2008_358
crossref_primary_10_1097_01_hjh_0000244949_65040_de
crossref_primary_10_1172_JCI5056
crossref_primary_10_2353_ajpath_2010_090574
crossref_primary_10_1161_HYPERTENSIONAHA_121_18181
crossref_primary_10_1016_j_yjmcc_2020_11_010
crossref_primary_10_1161_HYPERTENSIONAHA_121_17927
crossref_primary_10_1111_bph_12328
crossref_primary_10_1016_j_pharmthera_2006_10_001
crossref_primary_10_37871_jbres1208
crossref_primary_10_1016_j_healun_2010_03_016
crossref_primary_10_1161_JAHA_122_028201
crossref_primary_10_1128_MCB_23_22_8226_8232_2003
crossref_primary_10_4061_2011_535241
crossref_primary_10_1258_la_2007_06001e
crossref_primary_10_1016_j_cardiores_2006_11_033
crossref_primary_10_1253_circj_72_309
crossref_primary_10_1053_pcad_1999_0410265
crossref_primary_10_1161_HYPERTENSIONAHA_119_14079
crossref_primary_10_1017_S1047951111002034
crossref_primary_10_1006_bbrc_2000_2364
crossref_primary_10_1073_pnas_1001360107
crossref_primary_10_1152_ajpheart_00269_2005
crossref_primary_10_1152_physiolgenomics_00023_2006
crossref_primary_10_1152_ajpheart_00124_2004
crossref_primary_10_1002_dmrr_2295
crossref_primary_10_1097_FJC_0000000000000999
crossref_primary_10_1007_s11906_007_0026_2
crossref_primary_10_1016_j_yjmcc_2009_04_014
crossref_primary_10_1016_S1050_1738_02_00233_5
crossref_primary_10_1172_JCI0214190
crossref_primary_10_1253_circj_66_397
crossref_primary_10_1248_bpb_32_376
crossref_primary_10_1016_j_biocel_2008_02_020
crossref_primary_10_1093_cvr_cvu039
crossref_primary_10_1152_ajpheart_2000_279_6_H2939
crossref_primary_10_3389_fcell_2021_639509
crossref_primary_10_1067_mje_2002_124644
crossref_primary_10_1007_s10741_019_09860_8
crossref_primary_10_3390_cells12131780
crossref_primary_10_1073_pnas_100127897
crossref_primary_10_1038_sj_bjp_0706762
crossref_primary_10_1054_jcaf_2001_29785
crossref_primary_10_1038_nm1101_1236
crossref_primary_10_1253_circj_CJ_09_0465
crossref_primary_10_1186_1475_2840_12_169
crossref_primary_10_1097_00005344_200206000_00012
crossref_primary_10_1161_hc1002_105225
crossref_primary_10_1007_s11010_005_3781_x
crossref_primary_10_1016_j_mce_2013_03_006
crossref_primary_10_1161_CIRCRESAHA_113_302501
crossref_primary_10_1186_s41232_017_0046_5
crossref_primary_10_1002_mrm_20018
crossref_primary_10_1016_j_peptides_2016_07_003
crossref_primary_10_1016_j_pharmthera_2007_04_010
crossref_primary_10_1097_00001573_200005000_00002
crossref_primary_10_1016_S0006_291X_03_01357_3
crossref_primary_10_1016_j_yjmcc_2011_02_012
crossref_primary_10_1111_j_1440_1681_2008_04981_x
crossref_primary_10_1291_hypres_26_731
crossref_primary_10_1016_j_ejphar_2003_11_074
crossref_primary_10_1007_s00210_007_0215_1
crossref_primary_10_1016_j_yjmcc_2007_01_012
crossref_primary_10_1172_JCI7315
crossref_primary_10_1046_j_1523_1755_2000_00009_x
crossref_primary_10_1152_ajpheart_00474_2004
crossref_primary_10_1074_jbc_274_31_21840
crossref_primary_10_1007_s10557_005_5059_7
crossref_primary_10_1016_S0167_0115_00_00168_3
crossref_primary_10_1016_j_ajpath_2015_09_010
crossref_primary_10_1038_hr_2012_221
crossref_primary_10_1007_s12265_015_9646_0
crossref_primary_10_1038_s41598_018_21270_8
crossref_primary_10_1016_j_jss_2007_01_037
crossref_primary_10_1016_S1471_4914_03_00164_3
crossref_primary_10_1620_tjem_225_131
crossref_primary_10_1016_S1050_1738_00_00018_9
crossref_primary_10_1111_j_1440_1681_2007_04716_x
crossref_primary_10_1161_HYPERTENSIONAHA_122_20601
crossref_primary_10_1016_j_bbamem_2007_02_010
crossref_primary_10_1097_01_hjh_0000165623_72310_dd
crossref_primary_10_1007_s11886_008_0074_5
crossref_primary_10_1111_jcmm_15147
crossref_primary_10_1007_s11906_001_0083_x
crossref_primary_10_1016_S1043_2760_00_00279_4
crossref_primary_10_1038_hr_2010_229
crossref_primary_10_1038_labinvest_2010_190
crossref_primary_10_1186_1743_8977_10_49
crossref_primary_10_1177_14703203211003786
crossref_primary_10_1017_S1047951107000376
crossref_primary_10_1172_JCI13350
Cites_doi 10.1074/jbc.270.32.18719
10.1038/377744a0
10.1096/fasebj.10.5.8621062
10.1161/01.CIR.58.6.1072
10.1161/01.HYP.23.1_Suppl.I148
10.1161/res.78.5.829
10.1161/res.62.6.2454761
10.1172/JCI117675
10.1038/377748a0
10.1161/circ.89.5.8181146
10.1161/res.71.6.1423940
10.1172/JCI113989
10.1161/res.78.3.379
10.1074/jbc.271.6.3221
10.1161/res.69.2.1650297
10.1016/S0021-9258(19)50309-X
10.1016/0002-9149(84)90692-1
10.1152/ajpendo.1994.267.2.E260
10.1016/0002-9149(88)90892-2
10.1073/pnas.79.10.3310
10.1006/bbrc.1995.1973
10.1172/JCI118054
10.1161/res.72.6.8495545
10.1073/pnas.93.22.12490
10.1161/res.77.2.258
10.1161/circ.95.5.1253
10.1073/pnas.92.8.3521
10.1161/res.79.4.887
10.1016/S0021-9258(19)39631-0
10.1016/S0021-9258(17)35310-3
10.1016/0092-8674(93)90541-W
10.1152/ajpcell.1992.263.4.C838
10.1038/375146a0
10.1016/S0021-9258(18)31697-1
10.1016/0002-9149(84)90634-9
10.1161/res.73.3.8348688
10.1161/01.hyp.23.5.587
10.1161/01.RES.69.1.209
10.1172/JCI114924
10.1146/annurev.ph.55.030193.000415
10.1146/annurev.ph.54.030192.001303
10.1161/res.68.4.2009615
10.1093/eurheartj/4.suppl_A.143
10.1152/ajpheart.1990.259.2.H610
10.1016/S0006-291X(05)80983-0
10.1161/circ.83.6.1828192
ContentType Journal Article
Copyright 1998 INIST-CNRS
Copyright American Heart Association, Inc. May 19, 1998
Copyright_xml – notice: 1998 INIST-CNRS
– notice: Copyright American Heart Association, Inc. May 19, 1998
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
K9.
NAPCQ
U9A
7X8
DOI 10.1161/01.cir.97.19.1952
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Career and Technical Education (Alumni Edition)
MEDLINE - Academic
DatabaseTitleList MEDLINE
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1524-4539
EndPage 1959
ExternalDocumentID 29690260
10_1161_01_CIR_97_19_1952
9609089
2242332
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.-D
.3C
.55
.GJ
.XZ
.Z2
01R
08R
0R~
0ZK
18M
1CY
1J1
29B
2FS
2WC
354
40H
41~
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
6PF
71W
77Y
7O~
AAAXR
AAEJM
AAGIX
AAHPQ
AAJCS
AAMOA
AAMTA
AAPBV
AAQKA
AARTV
AASOK
AASXQ
AAUGY
AAWTL
AAXQO
AAYOK
ABASU
ABBUW
ABDIG
ABOCM
ABPMR
ABPTK
ABQRW
ABXVJ
ABZAD
ACCJW
ACDDN
ACEWG
ACGFO
ACGFS
ACILI
ACOAL
ACRKK
ACRZS
ACWDW
ACWRI
ACXNZ
ADBBV
ADCYY
ADFPA
ADGGA
ADNKB
AE3
AE6
AEBDS
AEETU
AENEX
AFCHL
AFDTB
AFFNX
AFUWQ
AGINI
AHMBA
AHOMT
AHRYX
AHVBC
AIJEX
AJIOK
AJJEV
AJNWD
AJNYG
AKALU
AKULP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
ASPBG
AVWKF
AWKKM
AYCSE
AZFZN
BAWUL
BOYCO
BQLVK
BS7
BYPQX
C1A
C45
CS3
DIK
DIWNM
DU5
DUNZO
E.X
E3Z
EBS
EEVPB
EJD
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FEDTE
FL-
FW0
GNXGY
GQDEL
GX1
H0~
H13
HZ~
H~9
IKREB
IKYAY
IN~
IPNFZ
IQODW
J5H
JF9
JG8
JK3
JK8
K-A
K-F
K8S
KD2
KMI
KQ8
L-C
L7B
M18
MVM
N4W
N9A
NEJ
N~7
N~B
N~M
O9-
OAG
OAH
OBH
OCB
OCUKA
ODA
ODMTH
OGEVE
OHH
OHT
OHYEH
OJAPA
OK1
OL1
OLB
OLG
OLH
OLU
OLV
OLW
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWBYB
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
PQQKQ
R58
RAH
RHF
RIG
RLZ
S4R
S4S
T8P
TEORI
TR2
TSPGW
UPT
V2I
VVN
W2D
W3M
W8F
WH7
WHG
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
YOC
YQJ
YSK
YXB
YYM
YYP
YZZ
ZA5
ZFV
ZGI
ZXP
ZY1
ZZMQN
~H1
AAAAV
AAIQE
AAUEB
ABJNI
ADHPY
AFEXH
AHQNM
AINUH
AJZMW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
K9.
NAPCQ
U9A
7X8
ID FETCH-LOGICAL-c551t-c981eec5d3787b7e294b86211a9f2da721c48788d176c2e855c7baf7aefc46c13
ISSN 0009-7322
IngestDate Fri Aug 16 21:29:42 EDT 2024
Thu Oct 10 20:09:11 EDT 2024
Fri Aug 23 01:07:28 EDT 2024
Sat Sep 28 08:39:05 EDT 2024
Sun Oct 29 17:08:51 EDT 2023
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 19
Keywords Heart
Pathogenesis
Rodentia
Cardiovascular disease
Pathology
Vertebrata
Optical microscopy
Mammalia
Mouse
Heart disease
Animal
Angiotensin II
Hypertrophy
Biological receptor
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c551t-c981eec5d3787b7e294b86211a9f2da721c48788d176c2e855c7baf7aefc46c13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.97.19.1952
PMID 9609089
PQID 212717208
PQPubID 24119
PageCount 8
ParticipantIDs proquest_miscellaneous_79904328
proquest_journals_212717208
crossref_primary_10_1161_01_CIR_97_19_1952
pubmed_primary_9609089
pascalfrancis_primary_2242332
PublicationCentury 1900
PublicationDate 1998-05-19
PublicationDateYYYYMMDD 1998-05-19
PublicationDate_xml – month: 05
  year: 1998
  text: 1998-05-19
  day: 19
PublicationDecade 1990
PublicationPlace Hagerstown, MD
PublicationPlace_xml – name: Hagerstown, MD
– name: United States
– name: Baltimore
PublicationTitle Circulation (New York, N.Y.)
PublicationTitleAlternate Circulation
PublicationYear 1998
Publisher Lippincott Williams & Wilkins
American Heart Association, Inc
Publisher_xml – name: Lippincott Williams & Wilkins
– name: American Heart Association, Inc
References 9609078 - Circulation. 1998 May 19;97(19):1890-2
e_1_3_2_26_2
e_1_3_2_49_2
e_1_3_2_28_2
(e_1_3_2_27_2) 1993; 45
e_1_3_2_41_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_22_2
e_1_3_2_45_2
e_1_3_2_24_2
e_1_3_2_9_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_18_2
e_1_3_2_39_2
(e_1_3_2_47_2) 1993; 264
e_1_3_2_1_2
e_1_3_2_54_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_52_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_3_2
e_1_3_2_14_2
e_1_3_2_35_2
e_1_3_2_50_2
e_1_3_2_48_2
(e_1_3_2_5_2) 1990; 259
e_1_3_2_29_2
(e_1_3_2_6_2) 1989; 11
e_1_3_2_40_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_25_2
e_1_3_2_46_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_17_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_53_2
e_1_3_2_32_2
e_1_3_2_51_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_13_2
e_1_3_2_55_2
e_1_3_2_2_2
(e_1_3_2_36_2) 1992; 197
References_xml – ident: e_1_3_2_29_2
  doi: 10.1074/jbc.270.32.18719
– ident: e_1_3_2_32_2
  doi: 10.1038/377744a0
– ident: e_1_3_2_26_2
  doi: 10.1096/fasebj.10.5.8621062
– volume: 197
  start-page: 393
  year: 1992
  ident: e_1_3_2_36_2
  publication-title: Biochem Biophys Res Commun
– ident: e_1_3_2_41_2
  doi: 10.1161/01.CIR.58.6.1072
– volume: 45
  start-page: 205
  year: 1993
  ident: e_1_3_2_27_2
  publication-title: Pharmacol Rev
– ident: e_1_3_2_37_2
  doi: 10.1161/01.HYP.23.1_Suppl.I148
– ident: e_1_3_2_25_2
  doi: 10.1161/res.78.5.829
– ident: e_1_3_2_33_2
  doi: 10.1161/res.62.6.2454761
– ident: e_1_3_2_16_2
  doi: 10.1172/JCI117675
– ident: e_1_3_2_31_2
  doi: 10.1038/377748a0
– ident: e_1_3_2_40_2
  doi: 10.1161/circ.89.5.8181146
– ident: e_1_3_2_45_2
  doi: 10.1161/res.71.6.1423940
– ident: e_1_3_2_38_2
  doi: 10.1172/JCI113989
– ident: e_1_3_2_39_2
  doi: 10.1161/res.78.3.379
– ident: e_1_3_2_24_2
  doi: 10.1074/jbc.271.6.3221
– ident: e_1_3_2_13_2
  doi: 10.1161/res.69.2.1650297
– ident: e_1_3_2_28_2
– volume: 11
  start-page: 1325
  year: 1989
  ident: e_1_3_2_6_2
  publication-title: Clin Exp Hypertens
– ident: e_1_3_2_20_2
  doi: 10.1016/S0021-9258(19)50309-X
– ident: e_1_3_2_8_2
  doi: 10.1016/0002-9149(84)90692-1
– ident: e_1_3_2_42_2
  doi: 10.1152/ajpendo.1994.267.2.E260
– ident: e_1_3_2_52_2
– ident: e_1_3_2_10_2
  doi: 10.1016/0002-9149(88)90892-2
– ident: e_1_3_2_3_2
  doi: 10.1073/pnas.79.10.3310
– ident: e_1_3_2_43_2
  doi: 10.1006/bbrc.1995.1973
– ident: e_1_3_2_21_2
  doi: 10.1172/JCI118054
– ident: e_1_3_2_46_2
  doi: 10.1161/res.72.6.8495545
– ident: e_1_3_2_55_2
  doi: 10.1073/pnas.93.22.12490
– ident: e_1_3_2_54_2
– volume: 259
  start-page: H324
  year: 1990
  ident: e_1_3_2_5_2
  publication-title: Am J Physiol
– ident: e_1_3_2_22_2
  doi: 10.1161/res.77.2.258
– ident: e_1_3_2_44_2
  doi: 10.1161/circ.95.5.1253
– ident: e_1_3_2_30_2
  doi: 10.1073/pnas.92.8.3521
– ident: e_1_3_2_34_2
  doi: 10.1161/res.79.4.887
– ident: e_1_3_2_18_2
  doi: 10.1016/S0021-9258(19)39631-0
– ident: e_1_3_2_53_2
– ident: e_1_3_2_19_2
  doi: 10.1016/S0021-9258(17)35310-3
– ident: e_1_3_2_23_2
  doi: 10.1016/0092-8674(93)90541-W
– ident: e_1_3_2_11_2
  doi: 10.1152/ajpcell.1992.263.4.C838
– ident: e_1_3_2_51_2
  doi: 10.1038/375146a0
– ident: e_1_3_2_50_2
  doi: 10.1016/S0021-9258(18)31697-1
– volume: 264
  start-page: H760
  year: 1993
  ident: e_1_3_2_47_2
  publication-title: Am J Physiol
– ident: e_1_3_2_9_2
  doi: 10.1016/0002-9149(84)90634-9
– ident: e_1_3_2_15_2
  doi: 10.1161/res.73.3.8348688
– ident: e_1_3_2_7_2
  doi: 10.1161/01.hyp.23.5.587
– ident: e_1_3_2_49_2
  doi: 10.1161/01.RES.69.1.209
– ident: e_1_3_2_12_2
  doi: 10.1172/JCI114924
– ident: e_1_3_2_17_2
  doi: 10.1146/annurev.ph.55.030193.000415
– ident: e_1_3_2_2_2
  doi: 10.1146/annurev.ph.54.030192.001303
– ident: e_1_3_2_14_2
  doi: 10.1161/res.68.4.2009615
– ident: e_1_3_2_4_2
  doi: 10.1093/eurheartj/4.suppl_A.143
– ident: e_1_3_2_1_2
  doi: 10.1152/ajpheart.1990.259.2.H610
– ident: e_1_3_2_35_2
  doi: 10.1016/S0006-291X(05)80983-0
– ident: e_1_3_2_48_2
  doi: 10.1161/circ.83.6.1828192
SSID ssj0006375
Score 2.099408
Snippet Many studies have suggested that the renin-angiotensin system plays an important role in the development of pressure overload-induced cardiac hypertrophy....
Background —Many studies have suggested that the renin-angiotensin system plays an important role in the development of pressure overload–induced cardiac...
BACKGROUND: Many studies have suggested that the renin-angiotensin system plays an important role in the development of pressure overload-induced cardiac...
BACKGROUNDMany studies have suggested that the renin-angiotensin system plays an important role in the development of pressure overload-induced cardiac...
SourceID proquest
crossref
pubmed
pascalfrancis
SourceType Aggregation Database
Index Database
StartPage 1952
SubjectTerms Angiotensin II - pharmacology
Animals
Aorta, Abdominal - physiology
Biological and medical sciences
Blood Pressure - drug effects
Cardiology. Vascular system
Cardiomegaly - etiology
Cardiomegaly - genetics
Cardiomegaly - physiopathology
Echocardiography
Heart
Heart failure, cardiogenic pulmonary edema, cardiac enlargement
Hypertension - complications
Hypertension - physiopathology
Medical sciences
Mice
Mice, Knockout
Polymerase Chain Reaction
Receptor, Angiotensin, Type 1
Receptors, Angiotensin - biosynthesis
Receptors, Angiotensin - deficiency
Receptors, Angiotensin - genetics
Receptors, Angiotensin - physiology
RNA, Messenger - biosynthesis
Signal Transduction
Transcription, Genetic
Title Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice
URI https://www.ncbi.nlm.nih.gov/pubmed/9609089
https://www.proquest.com/docview/212717208
https://search.proquest.com/docview/79904328
Volume 97
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbKkBASQrAxUcbAD4gHooQ4vxw_VgXUMBUktEl7InIcmwXRZErTh_Hn8JdyTpw0g05ivERVUltO7vP5zv7uDqFXIgqUYlTYMs-ZHUQKplQkiZ0pl-eEZxlvq5YsP0WLs-DjeXg-mfwasZY2TeaInzvjSv5HqnAP5KqjZG8h2aFTuAG_Qb5wBQnD9Z9k3MX21dL6DEP_UXHN7M03mmM1bwUvrAW4mXVTV_Ax252N8ltRtZz10koSSzuhFtGMOE1uqWrrpAT1qJnKS0OJG5IYFLUwhb521e8Z7ScseM3zLs6sKsRFUVeDTq9WJqomWa9lMeztXBTV92LVNkmuNVjwK13qydj52abcblF0MXuhbRRhr3aZTf0uANmRRtN6gR2EXSajXhV3VN0ecmykWAkLvdEirVPi7F4AItIGNTjz5IvDqEOYs206Trb9xyI4UBNbpygiqUtS6CJlNCUs1V3cQXc9ykJNG32XnAyrfeTTsK_Wp1_RnJxDF2__GsU12-fBJV_DNFRd_ZSbHZzW0Dl9hB4aDwXPOrg9RhNZ7qODWcmbanWFX-OWM9wexuyje0tDzThAX3sw4h6M2IARGzDiERhxUeIRGHGSYA1GTGa4ByPuwYg1GJ-gsw_vT-cL2xTvsAUY4Y0tWEykFGHuw5KQUemxIAPvmRDOlJdz6hEBvnIc54RGwpNxGAqacUW5VCKIBPEP0V5ZlfIpwq5SRAXc9QSngYooy-NMyjCPZAjecUin6E3_WdPLLkdLeqMYp-j42ocfWnjas_Dh-VEviNRM9XWqyyCApe_GU_RyeAp6WB-u8VJWm3VKwawLfA_-cdhJb-hY53R0Y_bsNqM8Qve3E-k52mvqjTwG67fJXrTw-w09t6vA
link.rule.ids 315,786,790,27955,27956
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pressure+Overload+Induces+Cardiac+Hypertrophy+in+Angiotensin+II+Type+1A+Receptor+Knockout+Mice&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Harada%2C+Koichiro&rft.au=Komuro%2C+Issei&rft.au=Shiojima%2C+Ichiro&rft.au=Hayashi%2C+Doubun&rft.date=1998-05-19&rft.issn=0009-7322&rft.eissn=1524-4539&rft.volume=97&rft.issue=19&rft.spage=1952&rft.epage=1959&rft_id=info:doi/10.1161%2F01.CIR.97.19.1952&rft.externalDBID=n%2Fa&rft.externalDocID=10_1161_01_CIR_97_19_1952
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon